Photoredox catalysis has emerged as a powerful strategy for C—O cross-coupling reactions. We herein report a new class of tridentate pyridinophane ligands .sup.RN3 that allow for detailed mechanistic studies of the photocatalytic C—O coupling reaction. The derived (.sup.RN3)Ni complexes are active C—O cross-coupling photocatalysts under mild conditions and without an additional photocatalyst. We also utilized the .sup.RN3 ligands to study the essential but so far putative steps involving paramagnetic Ni species in a proposed catalytic cycle: the oxidative addition of an aryl bromide to a Ni(I) species, the ligand exchange at a Ni(III) center, and the C—O reductive elimination from a Ni(III) species.

Photoredox catalysis has emerged as a powerful strategy for C—O cross-coupling reactions. We herein report a new class of tridentate pyridinophane ligands .sup.RN3 that allow for detailed mechanistic studies of the photocatalytic C—O coupling reaction. The derived (.sup.RN3)Ni complexes are active C—O cross-coupling photocatalysts under mild conditions and without an additional photocatalyst. We also utilized the .sup.RN3 ligands to study the essential but so far putative steps involving paramagnetic Ni species in a proposed catalytic cycle: the oxidative addition of an aryl bromide to a Ni(I) species, the ligand exchange at a Ni(III) center, and the C—O reductive elimination from a Ni(III) species.

Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.

Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.

The present invention relates to macrocyclic pyridotriazine derivatives and the prodrugs thereof, and the pharmaceutically acceptable salts, solvates or polymorph thereof, and the use of such compounds as a medicament, in particular in the prevention and/or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, and to the compositions or preparations for use as a medicament, more preferably for the prevention or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family.

The present invention relates to macrocyclic pyridotriazine derivatives and the prodrugs thereof, and the pharmaceutically acceptable salts, solvates or polymorph thereof, and the use of such compounds as a medicament, in particular in the prevention and/or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, and to the compositions or preparations for use as a medicament, more preferably for the prevention or treatment of viral infections caused by viruses belonging to the Orthomyxoviridae family.

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

The present invention provides a compound represented by Formula (I):

##STR00001##

wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R.sup.1 is halogen or the like; R.sup.2a and R.sup.2b are each independently hydrogen or the like; R.sup.3 is substituted or unsubstituted alkyl or the like; R.sup.4 is hydrogen or the like; and n is an integer of 1 to 3.

The present invention provides a compound represented by Formula (I):

##STR00001##

wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R.sup.1 is halogen or the like; R.sup.2a and R.sup.2b are each independently hydrogen or the like; R.sup.3 is substituted or unsubstituted alkyl or the like; R.sup.4 is hydrogen or the like; and n is an integer of 1 to 3.

This invention relates to macrocyclic deaza-purinones derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.